By: Adam Feuerstein | 07/07/14 - 11:23 AM EDT
Lief sold 223,525 shares of Arena stock at an average price of $5.85 per share, which grossed him $1.3 million, according to the Form 4 filing. Lief's divestment of Arena shares was done under a pre-arranged 10b5-1 trading plan, the filing also noted.
We can debate whether insider selling under 10b5-1 plans is really "hands off" or not (I tend to be a skeptic because these pre-arranged trading plans can be manipulated) but the optics of Lief's stock sale look bad given the significant under-performance of Arena's stock price amidst disappointing sales of the company's obesity pill Belviq. Lief dumping 40% of his Arena shares all at once when the stock is hitting new lows isn't exactly confidence inspiring.
Arena shares are down 8.5% to $5.34 in Monday trading.
On a related note, I guess we can now put to rest any hope that Eisai is planning to acquire Arena. Lief wouldn't be selling if there was any truth to the takeover conjecture floated in May.
With today's sell-off, Arena's stock performance year to date looks even worse:
ARNA data by YCharts
07/23/14 - 10:17 AM EDT
07/22/14 - 12:12 PM EDT
07/22/14 - 09:41 AM EDT
07/15/14 - 01:10 PM EDT
07/14/14 - 11:14 AM EDT
07/23/14 - 11:39 AM EDT
07/23/14 - 10:05 AM EDT
07/22/14 - 12:00 PM EDT
07/22/14 - 10:24 AM EDT
07/21/14 - 14:30 PM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.